Chapter 33 — Anti-Cancer Drugs Part I Pharmacology — Module 3 — Antimetabolites: Folate Antagonists, Fluoropyrimidines, Cytidine and Purine Analogs, and Hypomethylating Agents
1. Leucovorin is co-administered with 5-fluorouracil to increase tumor cell kill, yet the same drug is used to rescue normal cells after high-dose methotrexate. Integrating the mechanisms of both agents, which explanation accounts for how one molecule produces these opposite clinical effects?
A) Leucovorin is chemically altered before each use, becoming a thymidylate synthase inhibitor with 5-fluorouracil and a dihydrofolate reductase inhibitor with methotrexate
B) With 5-fluorouracil, leucovorin raises 5,10-methylenetetrahydrofolate, the cofactor that stabilizes the FdUMP-thymidylate synthase ternary complex, deepening inhibition; with methotrexate, the same reduced folate refills the tetrahydrofolate pool downstream of the blocked dihydrofolate reductase, rescuing normal cells
C) With both drugs leucovorin simply increases drug delivery to the tumor, but the tumor responds differently to each
D) With 5-fluorouracil leucovorin inhibits dihydropyrimidine dehydrogenase, while with methotrexate it inhibits glucarpidase
E) Leucovorin has no mechanistic role with either drug; the effects are coincidental
ANSWER: B
Rationale:
The apparent paradox resolves at the level of the folate pool. With 5-fluorouracil, leucovorin is converted to 5,10-methylenetetrahydrofolate, the cofactor in the FdUMP-thymidylate synthase ternary complex; more cofactor stabilizes the complex and deepens thymidylate synthase inhibition, increasing tumor kill. With methotrexate, dihydrofolate reductase is blocked, so leucovorin supplies already-reduced folate downstream of the block, refilling the tetrahydrofolate pool of normal cells and rescuing them. The same molecule acts at the same pathway but in two different mechanistic contexts.
Option B is correct because it integrates the cofactor-stabilizing role with 5-fluorouracil and the downstream pool-refilling rescue with methotrexate.
Option A: Option A is incorrect because leucovorin is not converted into enzyme inhibitors; it acts as a reduced folate in both settings.
Option C: Option C is incorrect because the effects arise from folate-pool mechanisms, not from increased drug delivery.
Option D: Option D is incorrect because leucovorin neither inhibits dihydropyrimidine dehydrogenase nor inhibits glucarpidase.
Option E: Option E is incorrect because leucovorin has a defined mechanistic role with both drugs.
2. A colorectal cancer regimen uses continuous-infusion 5-fluorouracil rather than bolus dosing. Reasoning from the schedule through the favored metabolite to the expected toxicity, which prediction is correct?
A) Sustained low concentrations favor FUTP (fluorouridine triphosphate) and RNA (ribonucleic acid) incorporation, so myelosuppression predominates
B) High peak concentrations favor FdUMP (fluorodeoxyuridine monophosphate), so cerebellar toxicity predominates
C) The schedule does not affect which metabolite predominates, so toxicity is unpredictable
D) Sustained low concentrations favor FdUMP and thymidylate synthase inhibition, so mucositis and hand-foot syndrome predominate over myelosuppression
E) Continuous infusion abolishes both metabolites, so no characteristic toxicity occurs
ANSWER: D
Rationale:
Continuous infusion maintains sustained, lower 5-fluorouracil concentrations that favor formation of FdUMP and thymidylate synthase inhibition. Following the chain from schedule to metabolite to toxicity, this predicts predominantly mucositis and hand-foot syndrome (palmar-plantar erythrodysesthesia) rather than the myelosuppression that follows high-peak bolus dosing.
Option D is correct because it correctly traces continuous infusion to FdUMP/thymidylate synthase inhibition and the resulting mucositis and hand-foot syndrome.
Option A: Option A is incorrect because RNA-incorporation (FUTP) and myelosuppression are favored by high-peak bolus dosing, not continuous infusion.
Option B: Option B is incorrect because high peaks are a feature of bolus dosing, and cerebellar toxicity is a cytarabine effect, not a 5-fluorouracil effect.
Option C: Option C is incorrect because schedule does shift which metabolite predominates.
Option E: Option E is incorrect because continuous infusion does not abolish the metabolites; it shifts the balance toward FdUMP.
3. Capecitabine is designed for tumor-preferential generation of 5-fluorouracil via thymidine phosphorylase. A clinician asks why a patient with dihydropyrimidine dehydrogenase (DPD) deficiency is still at high risk of severe toxicity from capecitabine. Integrating activation and catabolism, which explanation is correct?
A) Capecitabine ultimately produces 5-fluorouracil, which is catabolized by DPD regardless of where it was generated; a DPD-deficient patient cannot clear the resulting 5-fluorouracil, so systemic exposure and toxicity rise just as with intravenous 5-fluorouracil
B) Capecitabine bypasses 5-fluorouracil entirely, so DPD status is irrelevant
C) DPD activates capecitabine, so deficiency reduces its toxicity
D) Tumor-preferential activation means no 5-fluorouracil reaches the systemic circulation, so DPD deficiency cannot matter
E) DPD deficiency only affects methotrexate, not fluoropyrimidines
ANSWER: A
Rationale:
Tumor-preferential activation increases 5-fluorouracil generation at the tumor but does not change how 5-fluorouracil is eliminated: catabolism by dihydropyrimidine dehydrogenase (DPD) accounts for the majority of clearance wherever the drug is generated. A DPD-deficient patient cannot catabolize the 5-fluorouracil that capecitabine produces, so systemic exposure and the risk of severe toxicity rise just as they would with intravenous 5-fluorouracil. This integrates the activation pathway with the catabolic bottleneck.
Option A is correct because it links capecitabine-derived 5-fluorouracil to the DPD catabolic step that the deficient patient cannot perform.
Option B: Option B is incorrect because capecitabine acts precisely by generating 5-fluorouracil, so DPD status is highly relevant.
Option C: Option C is incorrect because DPD catabolizes (inactivates) 5-fluorouracil rather than activating capecitabine; deficiency increases, not decreases, toxicity.
Option D: Option D is incorrect because clinically significant systemic 5-fluorouracil exposure does occur, so DPD deficiency matters.
Option E: Option E is incorrect because DPD deficiency specifically affects fluoropyrimidines, not methotrexate.
4. A leukemic clone becomes resistant to both cytarabine and gemcitabine. Considering uptake, activation, and catabolism together, which single change would most plausibly confer resistance to both drugs at once?
A) Increased expression of thymidylate synthase
B) Amplification of dihydrofolate reductase
C) Loss of deoxycytidine kinase (dCK) activity, the shared activating enzyme both drugs require to form their active triphosphates
D) Increased reduced folate carrier expression
E) Loss of xanthine oxidase activity
ANSWER: C
Rationale:
Cytarabine and gemcitabine share the same activation requirement: phosphorylation by deoxycytidine kinase (dCK) to ultimately form their active triphosphates. Loss of dCK activity prevents activation of both drugs simultaneously and is therefore the single change most likely to confer cross-resistance. Their shared hENT1 (human equilibrative nucleoside transporter 1) uptake and inactivation by cytidine deaminase are also relevant, but loss of the shared activating enzyme directly disables both.
Option C is correct because dCK is the common activating enzyme for both cytidine analogs, so its loss confers resistance to both.
Option A: Option A is incorrect because thymidylate synthase relates to fluoropyrimidine and pemetrexed activity, not cytarabine or gemcitabine activation.
Option B: Option B is incorrect because dihydrofolate reductase amplification confers methotrexate resistance, not resistance to cytidine analogs.
Option D: Option D is incorrect because increased reduced folate carrier expression would, if anything, increase antifolate uptake and is unrelated to these cytidine analogs.
Option E: Option E is incorrect because loss of xanthine oxidase affects thiopurine catabolism, not cytarabine or gemcitabine.
5. Gemcitabine diphosphate inhibits ribonucleotide reductase. Reasoning forward through the consequences of that inhibition, which sequence correctly explains gemcitabine's self-potentiation?
A) Ribonucleotide reductase inhibition raises the dCTP (deoxycytidine triphosphate) pool, which competes more effectively with gemcitabine triphosphate, reducing incorporation
B) Ribonucleotide reductase inhibition blocks thymidylate synthase, depleting thymidylate and stopping the cell cycle independently of gemcitabine incorporation
D) Ribonucleotide reductase inhibition prevents gemcitabine from being phosphorylated by deoxycytidine kinase
E) Ribonucleotide reductase inhibition lowers the dCTP (deoxycytidine triphosphate) pool, reducing competition at DNA (deoxyribonucleic acid) polymerase and thereby increasing incorporation of gemcitabine triphosphate into DNA
ANSWER: E
Rationale:
Ribonucleotide reductase produces deoxyribonucleotides, including deoxycytidine triphosphate (dCTP). When gemcitabine diphosphate inhibits this enzyme, the dCTP pool falls. Because dCTP is the natural substrate competing with gemcitabine triphosphate at DNA (deoxyribonucleic acid) polymerase, less dCTP means less competition and therefore more efficient incorporation of gemcitabine triphosphate, a self-potentiating loop.
Option E is correct because it traces ribonucleotide reductase inhibition to a lower dCTP pool and then to enhanced gemcitabine incorporation.
Option A: Option A is incorrect because ribonucleotide reductase inhibition lowers, not raises, the dCTP pool.
Option B: Option B is incorrect because gemcitabine does not act through thymidylate synthase, and self-potentiation operates by reducing dCTP competition.
Option C: Option C is incorrect because the self-potentiation does not work by increasing catabolism; that would reduce activity.
Option D: Option D is incorrect because deoxycytidine kinase activation of gemcitabine is not blocked by ribonucleotide reductase inhibition.
6. 6-Mercaptopurine is inactivated by two routes: methylation by thiopurine methyltransferase (TPMT) and oxidation by xanthine oxidase (XO). Integrating both pathways, why is a patient with low TPMT activity who is also started on allopurinol at especially high risk?
A) Allopurinol increases TPMT activity, so the two effects cancel out
B) Both inactivating routes are simultaneously compromised — low TPMT reduces methylation while allopurinol inhibits xanthine oxidase — so 6-mercaptopurine is shunted heavily toward thioguanine nucleotide accumulation, producing severe myelosuppression
C) Low TPMT and allopurinol each increase 6-mercaptopurine catabolism, lowering drug levels
D) Allopurinol substitutes for TPMT, restoring normal methylation
E) The combination has no additive effect because the two pathways are independent and never overlap in importance
ANSWER: B
Rationale:
6-Mercaptopurine is inactivated by methylation (TPMT) and oxidation (xanthine oxidase). A low-TPMT patient already has impaired methylation; adding allopurinol inhibits xanthine oxidase, the other major catabolic route. With both inactivation pathways compromised, far more drug is channeled through HGPRT (hypoxanthine-guanine phosphoribosyltransferase) toward thioguanine nucleotide accumulation, producing severe, potentially fatal myelosuppression. The danger is the simultaneous loss of both routes.
Option B is correct because it integrates impaired methylation and inhibited oxidation as compounding losses of inactivation.
Option A: Option A is incorrect because allopurinol does not increase TPMT activity.
Option C: Option C is incorrect because both effects reduce catabolism and raise drug levels, not lower them.
Option D: Option D is incorrect because allopurinol does not substitute for TPMT methylation.
Option E: Option E is incorrect because the two pathways are both major inactivation routes, and losing both is strongly additive in risk.
7. Pemetrexed inhibits several folate-dependent enzymes and is extensively polyglutamated. Patients receive folic acid and vitamin B12 (cobalamin) supplementation. Integrating mechanism with the rationale for supplementation, which statement best explains why supplementation reduces toxicity without abolishing antitumor efficacy?
A) Correcting functional folate and B12 status preferentially protects rapidly dividing normal tissues (marrow, mucosa) from excessive folate-pathway inhibition, while the heavily polyglutamated drug retained in tumor cells continues to inhibit its targets
B) Folic acid and B12 chemically inactivate pemetrexed in the bloodstream before it reaches any tissue
C) Supplementation converts pemetrexed into methotrexate, which is less toxic
D) Folic acid blocks pemetrexed uptake into all cells equally, so both toxicity and efficacy fall proportionally
Much of pemetrexed's toxicity reflects excess inhibition of folate-dependent enzymes in rapidly dividing normal tissues, worsened by underlying functional folate or B12 deficiency. Repleting folate and B12 lessens this normal-tissue toxicity. Because pemetrexed is extensively polyglutamated and retained within tumor cells, antitumor target inhibition is largely preserved, so supplementation improves the therapeutic index rather than abolishing efficacy.
Option A is correct because it integrates normal-tissue protection with preserved tumor exposure from polyglutamate retention.
Option B: Option B is incorrect because the supplements do not chemically inactivate pemetrexed in plasma.
Option C: Option C is incorrect because supplementation does not convert pemetrexed into methotrexate.
Option D: Option D is incorrect because supplementation does not block uptake equally in all cells; it corrects functional folate status to protect normal tissue.
Option E: Option E is incorrect because B12 does not increase dihydropyrimidine dehydrogenase activity or accelerate pemetrexed catabolism.
8. A patient scheduled for high-dose methotrexate has a large pleural effusion, borderline renal function, and is taking a proton pump inhibitor and an NSAID (nonsteroidal anti-inflammatory drug). Integrating the factors that govern methotrexate exposure, why does this combination create a high risk of prolonged, toxic methotrexate levels?
A) The pleural effusion increases methotrexate metabolism, while the medications increase renal clearance
B) None of these factors affects methotrexate; only the infused dose matters
C) Methotrexate is cleared mainly by the kidney, so reduced renal function plus NSAID and proton pump inhibitor effects on renal elimination slow clearance, while the pleural effusion acts as a third-space reservoir that slowly releases methotrexate back into the circulation, together prolonging toxic exposure
D) The medications speed methotrexate elimination, so the only concern is the effusion
E) The effusion accelerates methotrexate clearance, offsetting the renal impairment
ANSWER: C
Rationale:
Three factors compound here. Methotrexate is eliminated chiefly by the kidney, so impaired renal function plus drugs that hinder renal elimination (NSAIDs, proton pump inhibitors) slow clearance. Separately, a large pleural effusion serves as a third-space reservoir that sequesters methotrexate and releases it slowly, sustaining plasma levels. Together these prolong toxic exposure, which is why effusions are drained and offending drugs are held before high-dose methotrexate.
Option C is correct because it integrates reduced renal clearance, drug effects on elimination, and the third-space reservoir effect.
Option A: Option A is incorrect because the effusion does not increase metabolism and the listed drugs do not increase renal clearance.
Option B: Option B is incorrect because these factors strongly influence methotrexate exposure beyond the infused dose.
Option D: Option D is incorrect because NSAIDs and proton pump inhibitors slow, not speed, methotrexate elimination.
Option E: Option E is incorrect because the effusion prolongs exposure rather than accelerating clearance.
9. In acute myeloid leukemia (AML) induction, cytarabine is given as a 7-day continuous infusion rather than as a single bolus. Integrating its S-phase specificity with the cell-cycle kinetics of leukemic blasts, why is the continuous-infusion schedule essential to efficacy?
A) Cytarabine is cell-cycle-nonspecific, so the schedule is arbitrary and only total dose matters
B) A bolus reaches every blast at once because all leukemic cells are simultaneously in S phase
C) Continuous infusion is used only to reduce nausea, not for any pharmacologic reason
D) Because only a fraction of blasts are in S phase at any moment, a sustained cytotoxic concentration over 7 days exposes each blast to drug as it cycles into S phase, whereas a bolus would spare cells entering S phase after the drug clears
E) Continuous infusion converts cytarabine into a cell-cycle-nonspecific agent that kills resting cells
ANSWER: D
Rationale:
Cytarabine is S-phase-specific, and at any instant only a fraction of leukemic blasts are in S phase. A bolus would kill that fraction but miss cells entering S phase after the drug cleared. A 7-day continuous infusion maintains a cytotoxic concentration so that each blast is exposed to drug whenever it cycles into S phase, which is the kinetic basis for the schedule. This integrates S-phase specificity with blast cell-cycle distribution.
Option D is correct because it links partial S-phase occupancy to the need for sustained exposure over the treatment window.
Option A: Option A is incorrect because cytarabine is S-phase-specific, so schedule is pharmacologically important.
Option B: Option B is incorrect because blasts are not all simultaneously in S phase.
Option C: Option C is incorrect because the schedule serves a pharmacologic, cell-cycle rationale, not merely antiemetic convenience.
Option E: Option E is incorrect because continuous infusion does not make cytarabine cell-cycle-nonspecific or enable killing of resting cells.
10. A patient with myelodysplastic syndrome shows no response after two cycles of azacitidine, and the team considers stopping. Integrating the drug's mechanism with the requirement for cell division, what is the best reasoning about continuing therapy?
A) Because the benefit depends on passive demethylation that accumulates only across successive cell divisions, several cycles are needed before silenced tumor suppressor genes are sufficiently demethylated; stopping at two cycles may abort a response that requires four to six cycles to emerge
B) Because azacitidine is directly cytotoxic like intensive chemotherapy, absence of response at two cycles proves permanent resistance
C) Because demethylation is complete after the first dose, two cycles without response means the mechanism has failed
D) Because the drug alkylates DNA (deoxyribonucleic acid), response should be immediate and further cycles are pointless
E) Because azacitidine works only in actively non-dividing cells, continued therapy cannot help
ANSWER: A
Rationale:
Hypomethylating agents act through passive demethylation, in which methylation marks are progressively lost from daughter strands over repeated cell divisions. Reactivating silenced tumor suppressor genes therefore requires multiple cycles, and the median time to response is several cycles, often four to six. Stopping at two cycles risks aborting a response that has not yet had time to develop, so continuation (if tolerated) is appropriate.
Option A is correct because it integrates the demethylation mechanism with the multi-division, multi-cycle requirement.
Option B: Option B is incorrect because at clinical doses the drug acts epigenetically rather than as a rapid direct cytotoxic, so early non-response does not prove resistance.
Option C: Option C is incorrect because demethylation is not complete after one dose; it accumulates over divisions.
Option D: Option D is incorrect because azacitidine does not act primarily by alkylation and response is not immediate.
Option E: Option E is incorrect because the mechanism requires cell division, not a non-dividing state.
11. Fludarabine and cladribine both deplete CD4 (cluster of differentiation 4) T-helper lymphocytes for a prolonged period. Integrating the type of immune deficit with the resulting infection risk, which prophylaxis strategy is appropriate and why?
A) No prophylaxis, because T-cell depletion does not predispose to infection
B) Prophylactic broad-spectrum antibacterials alone, because the deficit is purely neutrophil-related
C) Antifungal prophylaxis only, because the deficit affects neither viral nor Pneumocystis risk
D) Iron and erythropoietin, because the deficit is primarily anemia
E) Pneumocystis jirovecii pneumonia prophylaxis (typically trimethoprim-sulfamethoxazole) plus antiviral prophylaxis against herpesvirus reactivation, because prolonged CD4 T-cell depletion specifically predisposes to opportunistic infections characteristic of impaired cell-mediated immunity
ANSWER: E
Rationale:
The deficit produced by fludarabine and cladribine is prolonged depletion of CD4 T-helper lymphocytes, which impairs cell-mediated immunity. This pattern predisposes specifically to opportunistic infections such as Pneumocystis jirovecii pneumonia and herpesvirus reactivation. Matching prophylaxis to the deficit means Pneumocystis jirovecii pneumonia prophylaxis (commonly trimethoprim-sulfamethoxazole) plus antiviral prophylaxis against herpesvirus, continued during and for a period after therapy.
Option E is correct because it integrates the CD4 T-cell deficit with the opportunistic infections of impaired cell-mediated immunity and the matching prophylaxis.
Option A: Option A is incorrect because prolonged CD4 depletion clearly predisposes to opportunistic infection.
Option B: Option B is incorrect because the principal deficit is in cell-mediated immunity, not isolated neutropenia, so antibacterials alone are insufficient.
Option C: Option C is incorrect because the deficit does raise viral and Pneumocystis risk, so antifungal prophylaxis alone is inadequate.
Option D: Option D is incorrect because the characteristic deficit is T-cell depletion with infection risk, not primarily anemia.
12. Antimetabolite resistance arises by several mechanisms: reduced uptake, loss of an activating enzyme, amplification of the drug target, and upregulation of a catabolic enzyme. Integrating these, which pairing correctly matches a mechanism to its drug-specific consequence?
A) Increased cytidine deaminase activity causes methotrexate resistance
E) Loss of HGPRT (hypoxanthine-guanine phosphoribosyltransferase) causes methotrexate resistance
ANSWER: B
Rationale:
Different mechanisms map to different drugs. Amplification of the target dihydrofolate reductase increases enzyme available beyond what methotrexate can inhibit, causing methotrexate resistance (target amplification). Upregulation of the catabolic enzyme cytidine deaminase accelerates inactivation of cytarabine and gemcitabine, causing resistance to those cytidine analogs (catabolic upregulation). Pairing each mechanism with the correct drug is the integration tested.
Option B is correct because it correctly assigns dihydrofolate reductase amplification to methotrexate and cytidine deaminase upregulation to the cytidine analogs.
Option A: Option A is incorrect because increased cytidine deaminase affects cytidine analogs, not methotrexate.
Option C: Option C is incorrect because the reduced folate carrier transports methotrexate; its loss causes methotrexate (not cytarabine) resistance.
Option D: Option D is incorrect because thymidylate synthase amplification relates to fluoropyrimidine and pemetrexed resistance, not 6-mercaptopurine.
Option E: Option E is incorrect because loss of HGPRT causes thiopurine resistance (6-mercaptopurine, 6-thioguanine), not methotrexate resistance.
13. Two cytidine analogs each carry a characteristic non-hematologic toxicity that points to a different organ and mechanism. Integrating drug, target organ, and mechanism, which pairing correctly distinguishes them?
A) High-dose cytarabine causes interstitial pulmonary infiltrates from alveolar injury; gemcitabine causes cerebellar Purkinje cell loss
B) Both drugs cause cerebellar Purkinje cell injury, differing only in onset
C) High-dose cytarabine causes cerebellar toxicity (ataxia, dysarthria, nystagmus) from Purkinje cell injury, whereas gemcitabine characteristically causes pulmonary toxicity and, rarely, a thrombotic microangiopathy (hemolytic uremic syndrome)
D) Both drugs characteristically cause thrombotic microangiopathy, differing only in severity
The two toxicities localize to different organs by different mechanisms. High-dose cytarabine injures cerebellar Purkinje cells, producing ataxia, dysarthria, and nystagmus. Gemcitabine instead causes a characteristic pulmonary toxicity and, rarely, a thrombotic microangiopathy presenting as hemolytic uremic syndrome. Correctly mapping each drug to its organ and mechanism is the integration tested.
Option C is correct because it assigns cerebellar Purkinje injury to high-dose cytarabine and pulmonary/thrombotic microangiopathy toxicity to gemcitabine.
Option A: Option A is incorrect because it reverses the organs affected by each drug.
Option B: Option B is incorrect because cerebellar Purkinje injury is characteristic of cytarabine, not both drugs.
Option D: Option D is incorrect because thrombotic microangiopathy is a gemcitabine effect, not a shared characteristic toxicity.
Option E: Option E is incorrect because it reverses the two toxicities, assigning hemolytic uremic syndrome to cytarabine and ataxia to gemcitabine.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.